Document Preview Unavailable
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
You might have access to this document
-
Try and log in through your institution to see if they have access to the full text.
Log in through your library